CD27 and cancer: Suboptimal invigoration of T-cell in patients who suffer from cancer and are treated with PD-1 checkpoint blockers is enhanced through the combination of CD27 agonism and PD-1 blockade and provides mechanistic insight into how these techniques co-operate with each other to activate CD8+ T cell (Buchan et al., 2018[10]).